The Cost-effectiveness of canagliflozin (Cana) versus Saxagliptin (Saxa) among older Individuals living with type 2 diabetes mellitus (T2dm) In canada
May 1, 2015, 00:00
10.1016/j.jval.2015.03.365
https://www.valueinhealthjournal.com/article/S1098-3015(15)00422-2/fulltext
Title :
The Cost-effectiveness of canagliflozin (Cana) versus Saxagliptin (Saxa) among older Individuals living with type 2 diabetes mellitus (T2dm) In canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00422-2&doi=10.1016/j.jval.2015.03.365
First page :
A62
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1467